To elucidate mechanisms of TKI-resistance in tyrosine kinase-driven leukemia, we performed a gene expression analysis including our and published data of TKI-treated leukemia. We identified *BCL6* as a top-ranking gene in a set of recurrent gene expression changes[@R10], some of which are shared with MEK inhibition in BRAF^V600E^ mutant solid tumor cells[@R11] ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}--[3](#SD1){ref-type="supplementary-material"}). TKI-induced upregulation of BCL6 mRNA levels was confirmed in multiple leukemia subtypes carrying oncogenic tyrosine kinases ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). The BCR-ABL1 kinase, encoded by the Philadelphia chromosome (Ph), represents the most frequent genetic lesion in adult ALL, defines the subtype with a particularly poor prognosis[@R1],[@R4],[@R5] and was therefore chosen as focus for this study.

To elucidate the regulation of BCL6 in Ph^+^ ALL, we investigated the JAK2/STAT5[@R12] and PI3K/AKT[@R13] pathways downstream of BCR-ABL1. We and others have shown that STAT5 suppresses BCL6 in B cells[@R14]--[@R16]. TKI-mediated upregulation of BCL6 was diminished by constitutively active STAT5([Fig. 1b](#F1){ref-type="fig"}) and deletion of *STAT5* was sufficient to upregulate BCL6, even in the absence of TKI-treatment ([Fig. 1c](#F1){ref-type="fig"}). In agreement with previous work[@R16], overexpression of FoxO4 induced BCL6 ([Fig. 1d](#F1){ref-type="fig"}). In Ph^+^ ALL cells, FoxO factors are inactivated by PI3K/AKT[@R13] signaling, which is reversed by Pten ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Deletion of *Pten*, hence, abrogated the ability of the leukemia cells to upregulate BCL6 in response to TKI-treatment ([Fig. 1e](#F1){ref-type="fig"}).

In DLBCL, BCL6 is frequently translocated and suppresses p53-mediated apoptosis[@R9],[@R17]. While TKI-treatment is less effective in p53^−/−^ Ph^+^ ALL[@R18], recent studies showed that TKI paradoxically prevent the upregulation of p53 in response to DNA damage in Ph^+^ ALL and CML[@R19],[@R20]. A comparative gene expression analysis of BCL6^−/−^ and BCL6^+/+^ ALL cells ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}) identified Cdkn2a (Arf), Cdkn1a (p21), p53 and p53bp1 as potential BCL6 target genes ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). Arf and p53 protein levels were indeed unrestrained in BCL6^−/−^ ALL ([Fig. 2a](#F2){ref-type="fig"}). TKI-treatment of BCL6^+/+^ ALL resulted in strong upregulation of BCL6 with low levels of p53, while BCL6^−/−^ALL cells failed to curb p53 expression levels ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). Likewise, TKI-treatment increased excessively p53 levels when *Pten*-deficient ALL cells failed to upregulate BCL6 ([Fig. 1e](#F1){ref-type="fig"}).

Identifying direct targets of BCL6 by chromatin immunoprecipitation in Ph^+^ ALL ([Supplementary Fig. 8--11](#SD1){ref-type="supplementary-material"}), p53, p21 and p27 were among the genes with the strongest recruitment of BCL6 in TKI-treated ALL ([Fig. 2b](#F2){ref-type="fig"}; [Supplementary Fig. 9--11](#SD1){ref-type="supplementary-material"}). Given that cell cycle-arrest and senescence-associated genes were among the BCL6 targets, we studied the cell cycle profile of leukemia cells. BCL6^−/−^ ALL cells divided at a slightly reduced rate compared to BCL6^+/+^ ALL cells ([Fig. 2c](#F2){ref-type="fig"}). Treatment with adriamycin (0.05 μg/ml) had no significant effect on BCL6^+/+^ ALL cells in a senescence-associated β-galactosidase assay[@R21]--[@R22] but revealed that the vast majority of BCL6^−/−^ leukemia cells was poised to undergo cellular senescence ([Fig. 2d](#F2){ref-type="fig"}). These findings demonstrate that even low levels of BCL6 in the absence of TKI-treatment are critical to downregulate Arf/p53.

Clonal evolution of leukemia involves acquisition of genetic lesions through DNA damage[@R23]. Interestingly, a CGH analysis revealed that genetic lesions were less frequent in BCL6 deficient ALL ([Supplementary Fig. 12](#SD1){ref-type="supplementary-material"}), suggesting that increased sensitivity to DNA damage limits clonal evolution in the absence of BCL6. Since Arf and p53 are critical negative regulators of self-renewal[@R24], we performed colony-forming assays. The colony frequencies of BCL6^−/−^ ALL cells were reduced by \~20-fold compared to BCL6^+/+^ ALL ([Fig. 3a](#F3){ref-type="fig"}). To study self-renewal *in vivo*, we measured the ability of BCL6^+/+^ and BCL6^−/−^ ALL cells to initiate leukemia in transplant recipients ([Fig. 3b](#F3){ref-type="fig"}). Using luciferase bioimaging, leukemia engraftment was observed in both groups after 8 days. BCL6^+/+^ ALL cells rapidly expanded and initiated fatal leukemia, whereas BCL6^−/−^ ALL cells failed to expand from the initial engraftment foci ([Fig. 3c](#F3){ref-type="fig"}). Some mice that received BCL6^−/−^ ALL cells ultimately succumbed to leukemia ([Fig. 3b](#F3){ref-type="fig"}). Flow cytometry, however, revealed that the leukemias in the BCL6^−/−^ group were in fact derived from endogenous CD45.1^+^ cells of the irradiated recipients and not from the injected CD45.2^+^ donor ALL cells ([Supplementary Fig. 13](#SD1){ref-type="supplementary-material"}; asterisks in [Fig. 3b](#F3){ref-type="fig"}).

Defective leukemia-initiation may be a consequence of impaired homing to the bone marrow niche. Indeed, BCL6^−/−^ ALL cells lack expression of CD44 ([Supplementary Fig. 14](#SD1){ref-type="supplementary-material"}), which is critical for homing of *BCR-ABL1* leukemia-initiating cells (LIC) to the bone marrow microenvironment[@R25]. Retroviral reconstitution of CD44 markedly increased homing of BCL6^−/−^ ALL cells to the bone marrow niche, but failed to rescue defective leukemia-initiation ([Supplementary Fig. 14](#SD1){ref-type="supplementary-material"}).

Using intrafemoral injection to circumvent homing defects, a limiting dilution experiment ([Fig. 3d](#F3){ref-type="fig"}) showed that 5 million BCL6^−/−^ ALL cells compared to only 10^3^ BCL6^+/+^ ALL cells were needed to initiate fatal leukemia. These findings suggest that the frequency of LIC in BCL6^−/−^ ALL (\<1 in 100,000) is reduced by \>100-fold compared to BCL6^+/+^ ALL (≥1 in 1,000). An alternative interpretation would be that LIC occur at a similar frequency in BCL6^−/−^ ALL but with reduced self-renewal activity. To address potential "exhaustion" of LIC, we performed a serial transplantation with ALL cells that gave rise to disease in primary recipients after injection of 5 million ALL cells. From the bone marrow, we isolated CD19^+^ ALL cells for secondary intrafemoral injection. BCL6^−/−^ leukemia was not transplantable in secondary recipients ([Supplementary Fig. 15](#SD1){ref-type="supplementary-material"}). While these findings do not rule out the possibility that the LIC frequencies are reduced in BCL6^−/−^ ALL, they support the notion of LIC "exhaustion" after secondary transplantation.

To explore the therapeutic usefulness of pharmacological inhibition of BCL6, we tested a BCL6 inhibitor (RI-BPI), which blocks the repressor activity of BCL6[@R26]. Gene expression analysis confirmed that RI-BPI is a selective and potent inhibitor of BCL6 ([Supplementary Fig. 16](#SD1){ref-type="supplementary-material"}). We investigated the effect of RI-BPI on the self-renewal capacity of primary Ph^+^ ALL and the initiation of leukemia in a mouse xenograft model. Treatment with RI-BPI resulted in a reduction of colony formation and delayed progression of leukemia. Likewise, treatment of Ph^+^ ALL with RI-BPI induced cellular senescence ([Supplementary Fig. 17](#SD1){ref-type="supplementary-material"}).

We next examined how gene dosage of BCL6 affects responses to TKI. For instance, *Pten*^−/−^ ALL cells lack the ability to upregulate the p53-repressor BCL6 and are more sensitive to Imatinib ([Fig. 1e](#F1){ref-type="fig"}; [Supplementary Fig. 18](#SD1){ref-type="supplementary-material"}). Dose-response studies in BCL6^+/+^, BCL6^+/−^ and BCL6^−/−^ ALL ([Fig. 4a](#F4){ref-type="fig"}) showed that Imatinib-sensitivity was significantly increased in BCL6^−/−^ (EC~50~: 0.17 μmol/l) and even in BCL6^+/−^ ALL cells (EC~50~: 0.67 μmol/l) compared to BCL6^+/+^ ALL cells (EC~50~: 1.10 μmol/l; [Fig. 4a](#F4){ref-type="fig"}). These findings indicate that maximum levels of BCL6 expression are required to prevent TKI-induced cell death. Indeed, inducible activation of BCL6-ER^T2^ constructs[@R27] in BCL6^−/−^ ALL cells conferred a strong survival advantage in the presence of Imatinib ([Fig. 4b](#F4){ref-type="fig"}). Activation of BCL6 in BCL6^+/+^ ALL cells induced cell cycle exit (not shown) and no additional survival advantage, because these cells already achieved maximal upregulation of endogenous BCL6 ([Fig. 1a](#F1){ref-type="fig"}).

To address the role of BCL6-mediated repression of p53 in TKI-resistance, p53^−/−^ and p53^+/+^ ALL cells were treated with RI-BPI. The synergistic effect between TKI-treatment and RI-BPI is indeed partially p53-dependent ([Supplementary Fig. 19](#SD1){ref-type="supplementary-material"}). In p53^−/−^ ALL cells, the effect of RI-BPI was significantly diminished compared to p53^+/+^ ALL.

To confirm that BCL6 has a similar function in patient-derived Ph^+^ ALL, primary ALL cells were transduced with a dominant-negative BCL6 mutant (DN-BCL6-ER^T2^)[@R27], which resulted in a marked competitive disadvantage of Ph^+^ ALL cells, that was further enhanced by Imatinib treatment ([Fig. 4c](#F4){ref-type="fig"}). Similar observations in mouse ALL and in an established Ph^+^ ALL cell line demonstrate that BCL6 promotes survival of TKI-treated Ph^+^ ALL ([Supplementary Fig. 20](#SD1){ref-type="supplementary-material"}).

To test the effect of BCL6 inhibition on TKI-resistance, we cultured 4 primary Ph^+^ ALL in the presence or absence of Imatinib, RI-BPI or a combination of both ([Supplementary Fig. 21](#SD1){ref-type="supplementary-material"}). Initially, all 4 Ph^+^ ALL cases responded to Imatinib treatment, but subsequently rebounded and were no longer sensitive to Imatinib (10 μmol/l). RI-BPI alone showed only slight effects, while the combination of RI-BPI and Imatinib rapidly induced cell death and effectively prevented a rebound in all 4 cases ([Supplementary Fig. 21](#SD1){ref-type="supplementary-material"}). These findings suggest that prolonged treatment with a combination of Imatinib/RI-BPI prevents acquisition of TKI-resistance. We next examined the effect of Imatinib/RI-BPI combinations on primary TKI-resistance in Ph^+^ ALL. To this end, 4 human Ph^+^ ALL cell lines that lack *BCR-ABL1* kinase mutations ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) but are highly refractory to Imatinib (10 μmol/l) were treated with or without Imatinib, RI-BPI or a combination of both. Imatinib alone did not achieve a therapeutic response, whereas the combination with RI-BPI potentiated the effect of Imatinib on the refractory ALL cells ([Supplementary Fig. 22](#SD1){ref-type="supplementary-material"}).

To study the efficacy of combined tyrosine kinase and BCL6 inhibition *in vivo*, primary Ph^+^ ALL cells were labeled with luciferase and xenografted into mice. Recipient mice were treated with either vehicle, Nilotinib or a combination of Nilotinib and RI-BPI. Nilotinib is more potent than Imatinib, which only has marginal effects in mice[@R28],[@R29]. Bioimaging demonstrated that 7--10 injections of RI-BPI significantly enhanced the effect of Nilotinib ([Fig. 4d--e](#F4){ref-type="fig"} and [Supplementary Fig. 23](#SD1){ref-type="supplementary-material"}). While all mice treated with Nilotinib alone succumbed to leukemia within 99 days after injection, 7 of 8 mice treated with RI-BPI/Nilotinib combination were still alive after 140 days ([Fig. 4d--e](#F4){ref-type="fig"}). Also in a model for full-blown mouse leukemia, TKI/RI-BPI combinations proved effective and significantly prolonged survival ([Supplementary Fig. 24](#SD1){ref-type="supplementary-material"}). Establishing a potential therapeutic window of Nilotinib/RI-BPI combinations, we found no evidence of relevant toxicity ([Supplementary Fig. 25--26](#SD1){ref-type="supplementary-material"}; [Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

Although transcription factors have been considered intractable therapeutic targets, the recent development of a small molecule inhibitor against BCL6[@R30] holds promise to effectively target TKI-resistance in patients with Ph^+^ ALL. Since TKI-resistance develops in virtually all cases of Ph^+^ ALL, it appears particularly important to target this novel pathway of TKI-resistance.

Methods summary {#S1}
===============

Cell culture {#S2}
------------

Primary leukemia cells ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) were cultured on OP9 stroma cells in Alpha MEM without ribonucleotides and deoxyribonucleotides, supplemented with 20% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 IU/ml penicillin, and 100 μg/ml streptomycin. Human ALL cell lines were maintained in RPMI with GlutaMAX containing 20% FBS, 100 IU/ml penicillin, and 100 μg/ml streptomycin. Mouse *BCR-ABL1*-transformed ALL cells were maintained in IMDM with GlutaMAX containing 20% FBS, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 50 μM 2-mercaptoethanol. Cell cultures were kept at 37°C in a humidified incubator under a 5% CO~2~ atmosphere.

BCR-ABL1 transformation {#S3}
-----------------------

Transfection of a MSCV-based retroviral vector encoding BCR-ABL1 was performed using Lipofectamine 2000. Retroviral supernatant was produced by co-transfecting 293FT cells with the plasmids pHIT60 and pHIT123. Virus supernatant were harvested, filtered through a 0.45 μm filter and loaded by centrifugation (2,000 × g, 90 min at 32°C) on 50μg/ml RetroNectin coated non-tissue well plates. Extracted bone marrow cells from mice were transduced by *BCR-ABL1* in the presence of 10 ng/ml recombinant murine Interleukin-7 (IL-7) in RetroNectin-coated petri dishes.
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![Regulation of BCL6 expression in BCR-ABL1 ALL cells\
**a**, Ph^+^ ALL cells were treated with and without Imatinib (10 μmol/l) for 24 hours. Upregulation of BCL6 was compared to expression levels in DLBCL with *BCL6-IGH* translocation by Western blot. **b**, *BCR-ABL1*-transformed mouse ALL cells were transduced with a constitutively active Stat5 mutant (STAT5-CA) or a control vector (GFP) and treated either with or without Imatinib. BCL6 Western blot was performed using β-actin as loading control. **c**, BCL6 expression upon Imatinib-treatment was studied by Western blot in the presence or absence of Cre-mediated deletion of *Stat5* in *BCR-ABL1*-transformed Stat5^fl/fl^ mouse ALL. **d**, Mouse *BCR-ABL1* ALL cells were transduced with FoxO4-Puromycin or a Puromycin control vector and subjected to antibiotic selection. Cells were harvested and BCL6 mRNA levels were measured by qRT-PCR relative to Hprt. **e**, Imatinib-induced BCL6 expression was studied by Western blot in the presence or absence of Cre-mediated deletion of *Pten* in *BCR-ABL1*-transformed Pten^fl/fl^ mouse ALL cells.](nihms268753f1){#F1}

![BCL6 is required for transcriptional inactivation of the Arf/p53 pathway in BCR-ABL1 ALL\
**a**, Western blot analysis of CDKN2A (Arf) and p53 expression in BCL6^−/−^ and BCL6^+/+^ *BCR-ABL1* ALL cells. **b,** Human Ph^+^ ALL cells (Tom1) were treated with and without Imatinib (10 μmol/l) for 24 hours and were subjected to ChIP-on-chip analysis using a BCL6-specific antibody. The y-axis indicates enrichment versus input and the x-axis the location of probes within the respective loci relative to the transcriptional start site. The dark and light green (Control) or red (Imatinib) tracings depict two replicates. Recruitment to *CDKN1A*, *CDKN1B*, *TP53* and *HPRT* (negative control) is shown in Ph^+^ ALL cells and one DLBCL cell line (OCI-Ly7). **c**, Cell cycle analysis (BrdU/7-AAD staining). **d**, Staining for senescence-associated β-galactosidase (SA-β-gal). ALL cells were treated with or without 0.05 μg/ml adriamycin for 48 hours to induce a low level of DNA damage. Percentages of SA-β-gal^+^ cells are indicated (means ± SD; n=3).](nihms268753f2){#F2}

![BCL6 is required for leukemia-initiation in BCR-ABL1 ALL\
**a**, 10,000 BCL6^−/−^ or BCL6^+/+^ *BCR-ABL1* ALL cells were plated in semisolid agar, and colonies were counted after ten days (numbers denote means ± SD, n=3). **b**, Overall survival of mice injected with 100,000 BCL6^−/−^ and BCL6^+/+^ *BCR-ABL1* ALL cells was compared by Kaplan-Meier analysis. **c**, For a SCID leukemia-initiating cell (SL-IC) experiment, BCL6^−/−^ and BCL6^+/+^ *BCR-ABL1* ALL cells were labeled with firefly luciferase and were intravenously injected into sublethally irradiated NOD/SCID mice. Mice that developed CD45.1^+^ endogenous leukemia instead of leukemia from injected CD45.2^+^ cells are indicated by asterisks (see [Supplementary Fig. 13](#SD1){ref-type="supplementary-material"}). **d**, The SL-IC assay was repeated as a limiting dilution experiment (10^3^, 10^4^, 10^5^, 5 million cells) and leukemia cells were directly injected into the femoral bone marrow to circumvent potential engraftment defects.](nihms268753f3){#F3}

![BCL6 promotes survival of TKI-treated BCR-ABL1 ALL cells\
**a**, Imatinib-sensitivity of BCL6^−/−^, BCL6^+/−^ and BCL6^+/+^ ALL cells was measured in a Resazurin viability assay. **b**, BCL6^−/−^ ALL cells were transduced with BCL6-ER^T2^ or ER^T2^ vectors (tagged with GFP). ALL cells were treated with or without 1 μmol/l Imatinib, and BCL6-ER^T2^ or ER^T2^ were induced by 4-OHT. Relative changes of GFP^+^ cells after induction are indicated. **c**, Patient-derived Ph^+^ ALL cells (ICN1) were transduced with inducible dominant-negative BCL6 (DN-BCL6-ER^T2^) or ER^T2^ control vectors. ALL cells were treated with or without 10 μmol/l Imatinib and DN-BCL6-ER^T2^ or ER^T2^ were induced by 4-OHT. Relative changes of GFP^+^ cells after induction are indicated. **d**, Patient-derived Ph^+^ ALL cells (TXL2) were labeled with luciferase and 100,000 cells were injected. Mice were treated 7 times with either vehicle (gray), Nilotinib (25 mg/kg; green) or a combination of Nilotinib and RI-BPI (25 mg/kg; red). Treated mice are shown in **e**, a Kaplan-Meier survival analysis. Treatment days are indicated by arrow heads.](nihms268753f4){#F4}
